Aquestive Therapeutics, Inc. (AQST) stock
AQSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.78+0.08 (+2.16%)
Close on Nov 18, 2026Market cap $474.43MP/E –Yield –
Aquestive Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Aquestive Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $54.09M, up 22.6% year over year. For fiscal 2025 it was $44.55M, down 22.6% from the year before. The highest annual figure on record is $67.43M in fiscal 2018.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.55M | -22.6% |
| FY2024 | Dec 31, 2024 | $57.56M | +13.8% |
| FY2023 | Dec 31, 2023 | $50.58M | +6.1% |
| FY2022 | Dec 31, 2022 | $47.68M | -6.2% |
| FY2021 | Dec 31, 2021 | $50.83M | +10.9% |
| FY2020 | Dec 31, 2020 | $45.85M | -12.8% |
| FY2019 | Dec 31, 2019 | $52.61M | -22.0% |
| FY2018 | Dec 31, 2018 | $67.43M | +0.8% |
| FY2017 | Dec 31, 2017 | $66.92M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $13.82M | +38.1% |
| Q1 FY2026 | Mar 31, 2026 | $14.45M | +65.7% |
| Q4 FY2025 | Dec 31, 2025 | $13.02M | +9.7% |
| Q3 FY2025 | Sep 30, 2025 | $12.81M | -5.4% |
| Q2 FY2025 | Jun 30, 2025 | $10.00M | -50.2% |
| Q1 FY2025 | Mar 31, 2025 | $8.72M | -27.7% |
| Q4 FY2024 | Dec 31, 2024 | $11.87M | -10.1% |
| Q3 FY2024 | Sep 30, 2024 | $13.54M | +4.2% |
| Q2 FY2024 | Jun 30, 2024 | $20.10M | +51.8% |
| Q1 FY2024 | Mar 31, 2024 | $12.05M | +8.3% |
| Q4 FY2023 | Dec 31, 2023 | $13.21M | +23.6% |
| Q3 FY2023 | Sep 30, 2023 | $13.00M | +13.4% |
| Q2 FY2023 | Jun 30, 2023 | $13.24M | -0.2% |
| Q1 FY2023 | Mar 31, 2023 | $11.13M | -9.3% |
| Q4 FY2022 | Dec 31, 2022 | $10.68M | -3.6% |
| Q3 FY2022 | Sep 30, 2022 | $11.46M | -13.7% |
| Q2 FY2022 | Jun 30, 2022 | $13.27M | -13.6% |
| Q1 FY2022 | Mar 31, 2022 | $12.27M | +10.3% |
| Q4 FY2021 | Dec 31, 2021 | $11.08M | +55.0% |
| Q3 FY2021 | Sep 30, 2021 | $13.29M | +60.9% |
| Q2 FY2021 | Jun 30, 2021 | $15.35M | -29.2% |
| Q1 FY2021 | Mar 31, 2021 | $11.12M | +26.9% |
| Q4 FY2020 | Dec 31, 2020 | $7.15M | -56.5% |
| Q3 FY2020 | Sep 30, 2020 | $8.26M | -33.5% |
| Q2 FY2020 | Jun 30, 2020 | $21.68M | +94.8% |
| Q1 FY2020 | Mar 31, 2020 | $8.77M | -30.7% |
| Q4 FY2019 | Dec 31, 2019 | $16.42M | -2.4% |
| Q3 FY2019 | Sep 30, 2019 | $12.42M | -47.0% |
| Q2 FY2019 | Jun 30, 2019 | $11.13M | -8.7% |
| Q1 FY2019 | Mar 31, 2019 | $12.64M | -53.4% |
| Q4 FY2018 | Dec 31, 2018 | $16.82M | +51.0% |
| Q1 FY2018 | Mar 31, 2018 | $23.41M | +42.4% |
| Q4 FY2017 | Dec 31, 2017 | $12.19M | – |
| Q3 FY2017 | Sep 30, 2017 | $27.15M | – |
| Q2 FY2017 | Jun 30, 2017 | $11.14M | – |
| Q1 FY2017 | Mar 31, 2017 | $16.44M | – |
See a number that looks wrong?